@article{1590d828de7443ce9fb67d61756e972f,
title = "Response to {\textquotedblleft}Comment on: {\textquoteleft}When does atopic dermatitis warrant systemic therapy? Recommendations from an expert panel of the International Eczema Council{\textquoteright}{\textquotedblright}",
author = "Simpson, \{Eric L.\} and Reynolds, \{Nick J.\} and Carsten Flohr and Paller, \{Amy S.\} and Silverberg, \{Jonathan I.\} and Cork, \{Michel J.\} and Emma Guttman-Yassky and Irvine, \{Alan D.\}",
note = "Funding Information: Funding sources: Corporate sponsorship was provided to the International Eczema Council by Abbvie, Amgen, Celgene, Chugai, Galderma, Glaxo-SmithKline/Stiefel, the Leo Foundation, Leo Pharma, Lilly, MedImmune/Astrazeneca, Pfizer, Sanofi, Genzyme and Regeneron Pharmaceuticals, and Valeant. The cost of publication was covered by the International Eczema Council. ",
year = "2018",
month = aug,
day = "1",
doi = "10.1016/j.jaad.2018.03.048",
language = "English (US)",
volume = "79",
pages = "e25--e26",
journal = "Journal of the American Academy of Dermatology",
issn = "0190-9622",
publisher = "Elsevier Inc.",
number = "2",
}